This 3-year prospective observational study aims to identify clinical and laboratory risk factors associated with hospitalization in patients with confirmed dengue virus infection. It also seeks to analyze real-world transfusion practices and their outcomes. The study will be conducted in a second-level hospital in northern Mexico and will follow patients from emergency department entry to clinical resolution or hospital discharge.
This study will prospectively follow patients over 3 years to determine the relationship between clinical/laboratory variables and outcomes such as hospitalization and transfusion need. It seeks to improve understanding of real-world decision-making in transfusions for dengue-related thrombocytopenia and refine current hospitalization criteria based on locally observed predictors. Patients will be enrolled consecutively at emergency departments or outpatient clinics with confirmed dengue infection. Clinical data (fever duration, bleeding signs, vomiting, abdominal pain, platelet count, hematocrit) and transfusion records will be collected and analyzed to identify independent predictors using multivariate logistic regression.
Study Type
OBSERVATIONAL
Enrollment
100
Clinica Mexico
Piedras Negras, Coahuila, Mexico
RECRUITINGProportion of enrolled patients requiring hospitalization
The proportion of patients with laboratory-confirmed dengue infection who require hospitalization will be recorded. Hospitalization is defined as admission to the inpatient ward or intensive care unit for ≥24 hours due to dengue-related clinical indications. Unit of Measure: Percentage of participants (%)
Time frame: Time Frame: Within 10 days of symptom onset
Clinical and laboratory risk factors associated with hospitalization
Description: Among patients who are hospitalized, relevant clinical signs (e.g., persistent vomiting, mucosal bleeding, abdominal pain) and laboratory parameters (e.g., platelet count, hematocrit rise, leukopenia) will be analyzed to identify independent predictors for hospitalization using multivariate regression. Unit of Measure: Odds ratio for each factor (as determined by statistical modeling)
Time frame: Within 10 days of symptom onset
Proportion of patients receiving blood product transfusion
The proportion of participants who receive any blood product transfusion (platelets, red cells, plasma) will be documented. Transfusions must be indicated for dengue-related complications and recorded in the patient file. Unit of Measure: Percentage of participants (%)
Time frame: Time Frame: Within 14 days
Criteria for transfusion used by attending physicians
Documented clinical and laboratory criteria used to justify transfusion (e.g., platelet count \< 20,000/μL with bleeding, hemodynamic instability, or major hemorrhage) will be analyzed descriptively. No interventions will be assigned by the study team. Unit of Measure: Proportion of cases using each transfusion criterion (%)
Time frame: Within 14 days of symptom onset
JOSE IVAN RODRIGUEZ DE MOLINA SERRANO, MD, MSc, Ph, Specialist
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.